LXD1 Stock Overview
Designs, manufactures, and sells medical technology products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Inspiration Healthcare Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.19 |
| 52 Week High | UK£0.59 |
| 52 Week Low | UK£0.18 |
| Beta | 0.17 |
| 11 Month Change | 0% |
| 3 Month Change | -39.61% |
| 1 Year Change | -58.11% |
| 33 Year Change | -84.88% |
| 5 Year Change | n/a |
| Change since IPO | -85.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| LXD1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.8% |
| 1Y | -58.1% | -5.0% | 9.1% |
Return vs Industry: LXD1 underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: LXD1 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| LXD1 volatility | |
|---|---|
| LXD1 Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LXD1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LXD1's weekly volatility has decreased from 12% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 224 | Gordon Davis | www.inspiration-healthcare.com |
Inspiration Healthcare Group plc designs, manufactures, and sells medical technology products worldwide. The company offers products for acute care comprising developmental care, diagnostics, intensive care, monitoring, neonatal, obstetrics, operating theatres, pain management and developmental, respiratory, resus, thermo regulatory, and transport areas. It also offers infusion therapies for acute pain management, obstetrics, parenteral nutrition, palliative care, oncology, immunoglobulin therapy, antibiotic infusion, and other.
Inspiration Healthcare Group plc Fundamentals Summary
| LXD1 fundamental statistics | |
|---|---|
| Market cap | €16.91m |
| Earnings (TTM) | -€11.69m |
| Revenue (TTM) | €41.07m |
0.4x
P/S Ratio-1.4x
P/E RatioIs LXD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXD1 income statement (TTM) | |
|---|---|
| Revenue | UK£34.30m |
| Cost of Revenue | UK£18.91m |
| Gross Profit | UK£15.39m |
| Other Expenses | UK£25.16m |
| Earnings | -UK£9.76m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 44.88% |
| Net Profit Margin | -28.46% |
| Debt/Equity Ratio | 32.1% |
How did LXD1 perform over the long term?
See historical performance and comparison